Geode Capital Management’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$153K Buy
111,646
+14,904
+15% +$41.7K ﹤0.01% 4010
2025
Q4
$293K Buy
96,742
+4,661
+5% +$17.4K ﹤0.01% 3779
2025
Q3
$401K Buy
92,081
+190
+0.2% +$793 ﹤0.01% 3707
2025
Q2
$290K Buy
91,891
+1,387
+2% +$4.68K ﹤0.01% 3747
2025
Q1
$320K Buy
90,504
+3,531
+4% +$14.7K ﹤0.01% 3696
2024
Q4
$278K Sell
86,973
-462
-0.5% -$1.58K ﹤0.01% 3794
2024
Q3
$321K Buy
87,435
+1,088
+1% +$4.48K ﹤0.01% 3743
2024
Q2
$403K Sell
86,347
-1,027
-1% -$6.18K ﹤0.01% 3649
2024
Q1
$769K Sell
87,374
-7,662
-8% -$40.9K ﹤0.01% 3459
2023
Q4
$407K Hold
95,036
﹤0.01% 3692
2023
Q3
$324K Buy
95,036
+5,010
+6% +$22.8K ﹤0.01% 3782
2023
Q2
$508K Buy
90,026
+32,252
+56% +$167K ﹤0.01% 3633
2023
Q1
$279K Hold
57,774
﹤0.01% 3897
2022
Q4
$348K Sell
57,774
-135
-0.2% -$676 ﹤0.01% 3835
2022
Q3
$276K Buy
57,909
+345
+0.6% +$1.85K ﹤0.01% 4031
2022
Q2
$328K Buy
57,564
+521
+0.9% +$3.11K ﹤0.01% 3985
2022
Q1
$407K Hold
57,043
﹤0.01% 4046
2021
Q4
$455K Hold
57,043
﹤0.01% 4108
2021
Q3
$637K Buy
57,043
+1,564
+3% +$20.2K ﹤0.01% 3915
2021
Q2
$809K Buy
55,479
+9,649
+21% +$149K ﹤0.01% 3709
2021
Q1
$831K Buy
+45,830
New +$803K ﹤0.01% 3631

Other funds holding LTRN

Geode Capital Management's LTRN Position: Q1 2026 in Review

Geode Capital Management increased its Lantern Pharma (LTRN) stake by 15% in Q1 2026, buying an estimated $41.7K and bringing the position to 111,646 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #4010.

Geode Capital Management first reported a position in LTRN in Q1 2021 and has held it in 21 quarters since. The position peaked at $831K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Geode Capital Management held 111,646 shares of Lantern Pharma worth $153K as of Q1 2026.
  • Geode Capital Management bought 14,904 Lantern Pharma shares in Q1 2026, an estimated $41.7K.
  • Lantern Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4010 holding.
  • Geode Capital Management first reported a position in Lantern Pharma in Q1 2021 and has held it in 21 quarters since.
  • Geode Capital Management's Lantern Pharma position peaked at $831K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.